Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HEC73077 in Healthy Subjects
NCT05492630Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic nephropathy (DN) comparing HEC73077 with Placebo (2 arms). Primary endpoints: Adverse Events up to 19 days, Maximum Plasma Concentration and 1 more. Started May 2021; status: completed.
02
Drugs
rongliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT05492630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492630.